CLPT

Clearpoint Neuro, Inc. (CLPT) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Clearpoint Neuro is a commercial-stage medical device company focused on minimally invasive neurosurgical procedures and biologics/drug delivery services. The company operates in one reportable segment. In late 2025, the company acquired IRRAS Holdings, Inc., expanding its portfolio into neurocritical care with the IRRA flow system. The company is classified as a smaller reporting company and an accelerated filer.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2026): Net cash used in operating activities was $15.0 million. Net cash used in investing activities was $0.9 million. Net cash used in financing activities was $0.8 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 18% quarter-over-quarter (QoQ) and 30% year-over-year (YoY). This was driven by a 62% QoQ increase in Neurosurgery navigation and therapy revenue, attributed to the IRRA flow product and new operating room navigation software.
• Expense Increases: Operating expenses rose significantly. Sales and marketing expenses increased 68% QoQ and 72% YoY due to personnel expansion and amortization of acquired intangibles. General and administrative expenses increased 64% QoQ and 41% YoY, driven by occupancy costs and professional fees.
• Interest Expense: Interest expense surged to $1.4 million in Q2 2026 (from $0.4 million in Q2 2025) due to the issuance of notes payable in May and November 2025.
• Biologics Segment: Biologics and drug delivery revenue decreased 15% QoQ, primarily due to the non-recurrence of a single large customer order from the prior year.

Guidance, Outlook, and Risks

• Liquidity: Management believes cash balances of $29.4 million are sufficient to support operations for at least the next 12 months. The company has a cumulative deficit of $237.8 million.
• Debt Facilities: The company has a note purchase agreement allowing for up to $105.0 million in notes. As of June 30, 2026, approximately $48.1 million in net proceeds had been received. The notes bear interest at a minimum of 8.25% with a portion paid-in-kind (PIK) for the first six quarters.
• Capital Expenditures: The company is investing heavily in the ClearPoint Advanced Laboratories (CAL) facility in San Diego. Subsequent to the quarter end, the final phase of the lease became available, and purchase orders for $3.1 million in capital equipment were issued.
• Risks: Key risks include the execution risk and capital intensity of the CAL facility, dependence on pharmaceutical partners for biologics revenue, and the ability to access capital markets given the current loss position. There are no material pending legal proceedings.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $15.0 million operating cash burn over the next 12 months against the $29.4 million cash balance.
• Debt Covenants & PIK Interest: Review the terms of the $50.2 million note payable, specifically the payment-in-kind interest structure and the revenue participation fee (0.375% + 0.15%) starting in 2027.
• IRRAS Integration: Assess the revenue contribution of the IRRA flow system and whether the acquisition costs and amortization are impacting the path to profitability.
• CAL Facility ROI: Monitor the timeline for the ClearPoint Advanced Laboratories to become operational and generate revenue to offset the significant fixed costs and lease liabilities ($6.7 million liability recognized for the final phase).
• Biologics Volatility: Evaluate the concentration risk in the biologics segment, noting the revenue decline due to the absence of a single large order.